Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL208122 | 0.75 | AHR (0.32) | — | |
| SCHEMBL8613814 | 0.71 | KDM4E (0.40) | MAOB | |
| SCHEMBL207600 | 0.62 | AHR (0.37) | — | |
| SCHEMBL4306677 | 0.61 | — | — | |
| SCHEMBL3412034 | 0.60 | CYP1A2 (0.38) | MAOB | |
| SCHEMBL207898 | 0.59 | HDAC8 (0.30) | — | |
| SCHEMBL325358 | 0.59 | ALDH1A1 (0.41) | — | |
| SCHEMBL5206649 | 0.59 | PGR (0.38) | MAOB | |
| SCHEMBL978860 | 0.58 | TP53 (0.32) | — | |
| SCHEMBL208062 | 0.58 | MAP2K4 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048910-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-02-17 | — | — | US | claimed |
| EP-3946345-A1 | METHODS OF TREATING NEUROPATHIC PAIN | Intra-Cellular Therapies, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| CN-113905737-A | Method of treating neuropathic pain | 细胞内治疗公司 | 2022-01-07 | — | — | CN | claimed |
| EP-3914235-A2 | METHODS OF TREATING ADDICTION | Intra-Cellular Therapies, Inc. (US) | 2021-12-01 | — | — | EP | claimed |
| EP-3897621-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2021-10-27 | — | — | EP | claimed |
| CN-113329742-A | Method for treating addiction | 细胞内治疗公司 | 2021-08-31 | — | — | CN | claimed |
| WO-2020206391-A1 | METHODS OF TREATING NEUROPATHIC PAIN | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-10-08 | — | — | WO | claimed |
| WO-2020154519-A2 | METHODS OF TREATING ADDICTION | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-07-30 | — | — | WO | claimed |
| WO-2020132605-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-06-25 | — | — | WO | claimed |
| US-9238658-B2 | Substituted piperidinyl-carboxamide derivatives useful as SCD 1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-19 | — | — | US | claimed |
| EP-1776349-A2 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-25 | — | — | EP | claimed |
| US-20060079687-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-13 | — | — | US | claimed |
| WO-2006017836-A2 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-02-16 | — | — | WO | claimed |
| EP-0700396-A1 | PIPERIDINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1996-03-13 | — | — | EP | claimed |
| US-5478845-A | Inhibit dopamine or 5-hydroxytryptamine receptor binding | NOVO NORDISK A/S (DK) | 1995-12-26 | — | — | US | claimed |
| WO-1994027996-A1 | 1,2,5-THIADIAZOLE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-12-08 | — | — | WO | claimed |
| WO-1994027992-A1 | PIPERIDINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-12-08 | — | — | WO | claimed |
| WO-1994027994-A1 | PIPERIDINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-12-08 | — | — | WO | claimed |
| EP-0377528-B1 | Piperidines, process for their preparation and pharmaceutical compounds containing them | LIPHA (FR) | 1993-12-08 | — | — | EP | claimed |
| US-5001134-A | Piperidines, processes of preparation and medications containing them | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1991-03-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079687-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | BACE2, BACE1, APP | MAOB 532/4885 |
| US-20220048910-A1 | ORGANIC COMPOUNDS | OPRD1, OPRM1, HTR2C | MAOB 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.